Research progress on predictive indicators of the efficacy of novel endocrine therapy for metastatic hormone-sensitive prostate cancer
10.3760/cma.j.cn112330-20241102-00491
- VernacularTitle:转移性激素敏感性前列腺癌新型内分泌治疗疗效预测指标的研究进展
- Author:
Yiquan YANG
1
;
Lin QI
1
;
Yi CAI
1
Author Information
1. 中南大学湘雅医院泌尿外科，长沙 410008
- Publication Type:Journal Article
- Keywords:
Prostatic neoplasms;
Metastatic hormone-sensitive prostate cancer;
Novel hormone therapy;
Predictive indicators;
Prognosis
- From:
Chinese Journal of Urology
2025;46(3):233-236
- CountryChina
- Language:Chinese
-
Abstract:
Research has shown that the efficacy of androgen deprivation therapy in combination with novel hormonal therapies and chemotherapy can be predicted based on several biomarkers, including changes in PSA kinetics following treatment, expression levels of the androgen receptor and prostate-specific membrane antigen, circulating tumor cells, and gene mutations. Moreover, constructing a multivariate prediction model that incorporates tumor burden and metastasis timing can provide additional guidance for selecting appropriate treatment options. This article aims to provide robust evidence to support individualized treatment approaches for patients with metastatic hormone-sensitive prostate cancer (mHSPC).
